- Home
- AMSF vs AVBP Comparison
AMSF vs AVBP Comparison
Compare AMSF & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMSF
- AVBP
- Stock Information
- Founded
- AMSF 1985
- AVBP 2021
- Country
- AMSF United States
- AVBP United States
- Employees
- AMSF N/A
- AVBP N/A
- Industry
- AMSF Accident &Health Insurance
- AVBP
- Sector
- AMSF Finance
- AVBP
- Exchange
- AMSF Nasdaq
- AVBP NYSE
- Market Cap
- AMSF 984.1M
- AVBP 948.5M
- IPO Year
- AMSF 2005
- AVBP 2024
- Fundamental
- Price
- AMSF $51.31
- AVBP $27.07
- Analyst Decision
- AMSF Buy
- AVBP Strong Buy
- Analyst Count
- AMSF 2
- AVBP 5
- Target Price
- AMSF $59.50
- AVBP $36.80
- AVG Volume (30 Days)
- AMSF 138.7K
- AVBP 151.0K
- Earning Date
- AMSF 02-19-2025
- AVBP 02-02-2025
- Dividend Yield
- AMSF 2.87%
- AVBP N/A
- EPS Growth
- AMSF N/A
- AVBP N/A
- EPS
- AMSF 3.21
- AVBP N/A
- Revenue
- AMSF $315,182,000.00
- AVBP N/A
- Revenue This Year
- AMSF N/A
- AVBP N/A
- Revenue Next Year
- AMSF $0.88
- AVBP N/A
- P/E Ratio
- AMSF $16.05
- AVBP N/A
- Revenue Growth
- AMSF 2.81
- AVBP N/A
- 52 Week Low
- AMSF $41.97
- AVBP $14.35
- 52 Week High
- AMSF $60.24
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- AMSF 34.34
- AVBP 47.58
- Support Level
- AMSF $50.61
- AVBP $26.36
- Resistance Level
- AMSF $51.98
- AVBP $27.67
- Average True Range (ATR)
- AMSF 0.89
- AVBP 1.20
- MACD
- AMSF -0.14
- AVBP 0.13
- Stochastic Oscillator
- AMSF 22.51
- AVBP 78.34
About AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance to employers engaged in hazardous industries, mainly construction, trucking, manufacturing, oil and gas, and agriculture. The company generates a majority of its revenue in the form of premiums.
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.